147 related articles for article (PubMed ID: 2840194)
1. Late recurrence of primitive neuroectodermal tumor/medulloblastoma.
Lefkowitz IB; Packer RJ; Ryan SG; Shah N; Alavi J; Rorke LB; Sutton LN; Schut L
Cancer; 1988 Aug; 62(4):826-30. PubMed ID: 2840194
[TBL] [Abstract][Full Text] [Related]
2. Outcome for children treated for medulloblastoma and supratentorial primitive neuroectodermal tumor (CNS-PNET) - a retrospective analysis spanning 40 years of treatment.
Stensvold E; Krossnes BK; Lundar T; Due-Tønnessen BJ; Frič R; Due-Tønnessen P; Bechensteen AG; Myklebust TÅ; Johannesen TB; Brandal P
Acta Oncol; 2017 May; 56(5):698-705. PubMed ID: 28325133
[TBL] [Abstract][Full Text] [Related]
3. Collins' law. Prediction of recurrence or cure in childhood medulloblastoma?
Sure U; Berghorn WJ; Bertalanffy H
Clin Neurol Neurosurg; 1997 May; 99(2):113-6. PubMed ID: 9213055
[TBL] [Abstract][Full Text] [Related]
4. Management of children with primitive neuroectodermal tumors of the posterior fossa/medulloblastoma.
Packer RJ; Sutton LN; D'Angio G; Evans AE; Schut L
Pediatr Neurosci; 1985-1986; 12(4-5):272-82. PubMed ID: 3039477
[TBL] [Abstract][Full Text] [Related]
5. Relapse patterns in pediatric embryonal central nervous system tumors.
Perreault S; Lober RM; Carret AS; Zhang G; Hershon L; Décarie JC; Yeom K; Vogel H; Fisher PG; Partap S
J Neurooncol; 2013 Nov; 115(2):209-15. PubMed ID: 23921420
[TBL] [Abstract][Full Text] [Related]
6. Results of treatment of children with recurrent medulloblastoma/primitive neuroectodermal tumors with lomustine, cisplatin, and vincristine.
Lefkowitz IB; Packer RJ; Siegel KR; Sutton LN; Schut L; Evans AE
Cancer; 1990 Feb; 65(3):412-7. PubMed ID: 2153428
[TBL] [Abstract][Full Text] [Related]
7. Recurrence of medulloblastoma: violation of Collins' law after two decades.
Friedberg MH; David O; Adelman LS; Heilman CB
Surg Neurol; 1997 Jun; 47(6):571-4. PubMed ID: 9167782
[TBL] [Abstract][Full Text] [Related]
8. Medulloblastoma: survival and late recurrence after the Collins' risk period.
Nishio S; Morioka T; Takeshita I; Fukui M
Neurosurg Rev; 1997; 20(4):245-9. PubMed ID: 9457719
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy for medulloblastoma/primitive neuroectodermal tumors of the posterior fossa.
Packer RJ
Ann Neurol; 1990 Dec; 28(6):823-8. PubMed ID: 2178331
[TBL] [Abstract][Full Text] [Related]
10. Medulloblastoma: presentation, diagnosis and management.
Packer RJ; Finlay JL
Oncology (Williston Park); 1988 Sep; 2(9):35-45, 48-9. PubMed ID: 3275066
[TBL] [Abstract][Full Text] [Related]
11. Hypofractionated stereotactic radiotherapy in the management of recurrent or residual medulloblastoma/PNET.
Saran F; Baumert BG; Creak AL; Warrington AP; Ashley S; Traish D; Brada M
Pediatr Blood Cancer; 2008 Mar; 50(3):554-60. PubMed ID: 17941071
[TBL] [Abstract][Full Text] [Related]
12. Medulloblastoma. Period of risk reviewed.
Latchaw JP; Hahn JF; Moylan DJ; Humphries R; Mealey J
Cancer; 1985 Jan; 55(1):186-9. PubMed ID: 3965079
[TBL] [Abstract][Full Text] [Related]
13. High-dose chemotherapy with autologous stem cell rescue for children with high risk and recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors.
Pérez-Martínez A; Lassaletta A; González-Vicent M; Sevilla J; Díaz MA; Madero L
J Neurooncol; 2005 Jan; 71(1):33-8. PubMed ID: 15719272
[TBL] [Abstract][Full Text] [Related]
14. High-dose chemotherapy and autologous hematopoietic progenitor cell rescue in children with recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors: the impact of prior radiotherapy on outcome.
Butturini AM; Jacob M; Aguajo J; Vander-Walde NA; Villablanca J; Jubran R; Erdreich-Epstein A; Marachelian A; Dhall G; Finlay JL
Cancer; 2009 Jul; 115(13):2956-63. PubMed ID: 19402050
[TBL] [Abstract][Full Text] [Related]
15. The applicability of Collins' Law to childhood brain tumors and its usefulness as a predictor of survival.
Brown WD; Tavaré CJ; Sobel EL; Gilles FH
Neurosurgery; 1995 Jun; 36(6):1093-6. PubMed ID: 7643986
[TBL] [Abstract][Full Text] [Related]
16. Risk factors of recurrence in 157 MB/PNET patients treated in one institution.
Perek D; Perek-Polnik M; Drogosiewicz M; Dembowska-Bagińska B; Roszkowski M; Barszcz S
Childs Nerv Syst; 1998 Oct; 14(10):582-6. PubMed ID: 9840383
[TBL] [Abstract][Full Text] [Related]
17. Medulloblastoma and Collins' law: a critical review of the concept of a period of risk for tumor recurrence and patient survival.
Brown WD; Tavaré CJ; Sobel EL; Gilles FH
Neurosurgery; 1995 Apr; 36(4):691-7. PubMed ID: 7596498
[TBL] [Abstract][Full Text] [Related]
18. MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma.
Grotzer MA; Hogarty MD; Janss AJ; Liu X; Zhao H; Eggert A; Sutton LN; Rorke LB; Brodeur GM; Phillips PC
Clin Cancer Res; 2001 Aug; 7(8):2425-33. PubMed ID: 11489822
[TBL] [Abstract][Full Text] [Related]
19. Role of spinal MRI in the follow-up of children treated for medulloblastoma.
Bartels U; Shroff M; Sung L; Dag-Ellams U; Laperriere N; Rutka J; Bouffet E
Cancer; 2006 Sep; 107(6):1340-7. PubMed ID: 16894528
[TBL] [Abstract][Full Text] [Related]
20. Recurrence of medulloblastoma 19 years after the initial diagnosis.
Amagasaki K; Yamazaki H; Koizumi H; Hashizume K; Sasaguchi N
Childs Nerv Syst; 1999 Sep; 15(9):482-5. PubMed ID: 10502011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
